GSK3β suppresses cell growth, the epithelial-mesenchymal transition, and drug-resistance in breast cancer by inhibiting the GSK3β-β-catenin signaling pathway6,7, and its inactivation is found in approximately half of invasive mammary carcinomas8. Here, GSK3B is linked to breast carcinoma.